Clinical Trials Sponsored by Ascenta Therapeutics

Total 6488 results

Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Ascend Biopharmaceuticals Ltd

Suspended

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Basal Cell Carcinoma in Basal Cell Nevus Syndrome

United States
Acerta Pharma BV

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Healthy Participants

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Acerta Pharma BV

Completed

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Rheumatoid Arthritis

United States
Ascentage Pharma Group Inc.

Recruiting

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

CLL/SLL

China
Ascentage Pharma Group Inc.

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL

Russian Federation
Ascentage Pharma Group Inc.

Recruiting

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | B Cell Lymphoma | Mesothelioma | Non Hodgkin Lymphoma | Ovarian Clear Cell Carcinoma | Epithelioid Sarcoma | Castrate Resistant Prostate Cancer

United States
Ascentage Pharma Group Inc.

Recruiting

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Ascentage Pharma Group Inc.

Recruiting

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Breast Cancer | Solid Tumor, Adult

United States
Ascentage Pharma Group Inc.

Recruiting

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Advanced Pancreatic Cancer

China
Ascentage Pharma Group Inc.

Recruiting

A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Hepatitis B | HBV | Chronic Hep B

China
Ascentage Pharma Group Inc.

Recruiting

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China
Ascentage Pharma Group Inc.

Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

CLL/SLL

United States, Australia
Dascena
Cabell Huntington Hospital

Completed

Predictive algoRithm for EValuation and Intervention in SEpsis (PREVISE)

Sepsis | Septic Shock | Severe Sepsis

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Acerta Pharma BV

Terminated

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Ascend Biopharmaceuticals Ltd

Completed

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001)

Basal Cell Nevus Syndrome | Skin Neoplasm | Nodular Basal Cell Carcinoma of Skin

Australia
Ascentage Pharma Group Inc.

Not yet recruiting

A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML (POLARIS-2)

Chronic Myeloid Leukemia | CML | CML, Chronic Phase

United States
Ascentage Pharma Group Inc.

Recruiting

A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Anemia

China
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

AML, Adult

Australia, United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Amyloidosis

United States
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Ascentage Pharma Group Inc.

Recruiting

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Advanced Solid Tumors or Hematologic Malignancies

United States
Ascentage Pharma Group Inc.

Completed

APG-115 in Patients With Advanced Solid Tumors or Lymphomas (APG-115)

Patients With Advanced Solid Tumor or Lymphoma

United States
Ascentage Pharma Group Inc.

Terminated

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Australia
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
AstraZeneca
Acerta Pharma BV

Completed

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Infectious Disease

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Multiple Myeloma | Non-Hodgkins Lymphoma | B-All

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Canada, Italy
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
AstraZeneca
Acerta Pharma, LLC

Completed

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Pharmacokinetics | Bioavailability

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Lymphoma, Mantle Cell

United States, France, Italy, Taiwan, Mexico, Russian Federation, Vietnam, Belgium, Canada, Brazil, Hungary, Japan, Poland, China, Spain, Germany, Australia, Czechia, Korea, Republic of, Israel, Romania, Ukraine, Argentina, Peru, New Zealand and more

Clinical Trials Sponsored by Ascenta Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations